Start with the drug and the biomarker, not the drug name alone
Targeted cancer treatment acts on particular molecular features of a tumour. That single sentence explains why a useful conversation cannot begin with a drug name alone. The same medicine may be discussed for different tumour types, different molecular findings and different stages of treatment, and the risk-and-benefit discussion changes accordingly.
Before you ask about risks, make sure the clinician has the context that makes the question meaningful. That means the confirmed diagnosis and stage, the specific biomarker or molecular finding being used, the laboratory that produced the result and the date, and the treatments you have already received. If a biomarker result came from an overseas laboratory, ask whether the centre wants the original report, a re-review, or a fresh sample. Do not assume a result is transferable or actionable until the treating team says so.
A precise opening question is: "For my tumour type and this specific biomarker result, what is the evidence that this targeted therapy helps, and how strong is that evidence?" This invites the clinician to separate established use from experimental or off-label discussion. It also avoids the trap of asking whether a drug "works" in general, which cannot be answered for an individual.
Ask about risks in categories the clinician can actually answer
Patients often ask "what are the side effects?" and receive a list that is hard to weigh. A more useful approach is to ask the clinician to organise risks into categories: effects that are common and manageable, effects that are serious even if uncommon, effects that require stopping treatment, and effects that interact with your other conditions or medicines.
Ask specifically how each risk would be monitored, what symptoms should prompt you to contact the team urgently, and what the plan would be if a serious effect occurred. Ask whether any of your existing health problems — kidney function, liver function, heart conditions, prior lung disease, pregnancy or breastfeeding status — change the risk profile. Ask how the proposed therapy interacts with medicines you already take, including anything you buy without prescription.
You can also ask the team to quantify risk in the way they normally do in consent discussions. Clinicians can discuss evidence-based estimates and the uncertainty around them; an editorial article cannot give you a percentage for your situation, but your treating clinician can explain what is known. Ask: "What is the range of benefit and harm reported in the evidence you are relying on, and how confident are you that it applies to me?"
Ask what the alternatives are, including doing less
Alternatives are not only other drugs. They include other targeted agents, immunotherapy, chemotherapy, radiotherapy, surgery, clinical trial participation, watchful waiting, and best supportive care focused on symptoms and quality of life. Ask the team to compare the proposed targeted therapy with each realistic alternative in terms of expected benefit, expected harm, monitoring burden and effect on daily life.
Ask directly: "If I chose not to start this targeted therapy now, what would happen, and what would we watch?" This is a legitimate question and it clarifies whether the treatment is urgent, optional or one of several reasonable paths. Ask whether a different sequence — for example, a different treatment first — is a recognised option in your situation.
If a clinical trial is mentioned, treat it as a separate question. Being reviewed for a trial is not the same as being enrolled, and enrolment depends on the trial's own eligibility criteria, the sponsor's rules and the site's capacity. Ask what would need to be confirmed before any trial enrolment could be considered.
Confirm whether the centre can assess your case and how treatment would continue
A records-based opinion and a treatment plan are different things. Before travelling, ask whether the centre can review your case from records, what records it needs, and whether it can confirm that the specific drug or approach is available for your situation. Ask who would be responsible for the decision and what would still need to be confirmed in person.
If you are already receiving a targeted therapy elsewhere, the continuity question matters as much as the drug question. Ask how the centre would handle an ongoing treatment schedule, how monitoring tests would be arranged, how results would be communicated, and what would happen if a medicine were unavailable or interrupted. Ask whether the centre can continue your current regimen or whether it would recommend a change, and on what evidence.
Ask for the answer in writing where possible. A written summary of what the centre can and cannot confirm — before you commit to travel — is more useful than a verbal impression. If the centre cannot confirm a key point, that is itself important information for your decision.
- Which specific drug or class is being discussed, and for which biomarker result?
- Can the centre review your records remotely, and what does it need?
- Can it confirm availability of the proposed therapy for your situation?
- How would monitoring and ongoing treatment be arranged?
- What would still need to be confirmed in person?
Prepare a short question list and a records summary
A focused question list keeps a consultation from drifting. Write your three most important questions at the top, then supporting questions underneath. Bring a one-page summary of your diagnosis, stage, biomarker results, treatments received and current medicines, with dates. Bring the original pathology and molecular reports if you have them, plus recent imaging and blood results.
Ask the clinician to correct your summary if anything is wrong. This is a simple way to check that the team is working from the same facts you are. If a record is missing, ask what it would change and whether it is needed before a decision. Do not assume that an incomplete file means no assessment is possible; ask what can be assessed now and what must wait.
If language is a barrier, arrange interpretation for the clinical discussion itself, not only for logistics. Ask that the interpreter be present for the consent conversation and for any discussion of risks, alternatives and monitoring. Ask for key instructions in writing in a language you can read.
What an initial enquiry can and cannot do
An initial enquiry is a non-clinical step. It can help clarify your main question, identify missing information and suggest a relevant next step. It is not a diagnosis, a treatment recommendation or a promise that a hospital will accept your case. A proxy consultation, where a doctor takes your records to a specialist while you remain at home, is optional and not a prerequisite for every appointment.
The hospital and its licensed clinicians decide suitability, prescriptions, monitoring and treatment. Coordination services can help with appointments, interpretation and practical arrangements, but they do not decide clinical questions. If your symptoms worsen or you need urgent care, seek local medical attention rather than waiting for an overseas enquiry.
A practical next step is to write your three key questions and gather the records that support them. Then send a brief summary through the enquiry form, email or WhatsApp. You do not need to send a complete medical archive or payment details at first contact; the team can explain how to share records after the initial reply.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.